[Comparative immunohistochemical study of the HER2 status of breast cancer, by using the standard HercepTest kit and c-erbB2 antibodies].
The concordance of results of an immunohistochemical study using concentrated c-erbB2 antibodies and the HercepTest kit was studied on 80 invasive breast ductal carcinoma biopsy specimens by an immunohistological technique and hybridization in situ. The concordance of the techniques being examined was 75%. Antibodies to c-erbB2 are proposed to use for primary breast screening and the HercepTest kit should be employed to monitor Hercept-positive patients.